SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?


To: LLCF who wrote (249)2/9/1999 9:55:00 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 804
 
BMY drops ENMD and Angiostatin, after they passed early on Endostatin and canceled thalidomide (because CELG was first in market) . So what is next step. License something (in angiogenesis) which have real perspective. Like CELG's or SUGN's programs.

Hope market will not overreact with other cancer companies, but ENMD will be shorted everywhere.

biz.yahoo.com